SMARCA4 and neoplasm: Tumors harboring SMARCA4 mutations exhibit increased OXPHOS, and the use of OXPHOS inhibitors, such as IACS-010759, can reduce OXPHOS activity, leading to tumor cell death and decreased tumor progression (26).